The structure of nocamycin, a new antitumor antibiotic, has been elucidated with the aid of mass-and PMR-spectroscopic investigation of the antibiotic and its various chemical transformation products. Nocamycin is structurally related to tirandamycins.
Recently the isolation and physico-chemical characteristics of nocamycin have been reported1,2).
In this paper we report on studies dealing with the structural elucidation of nocamycin, which has resulted in the assignment of structure 1 to this new antibiotic.
The mass spectrum of nocamycin showed a molecular ion at 503.21607 (calcd. for C26H33NO9 503.21553). The characteristic fragment ions of nocamycin are depicted in Scheme 1 ; the respective mass spectral data are given in Table 1 .
Ion m/e 221 which gives rise to the base peak in the 70 and 12.5 eV mass spectra of 1 is formed by the cleavage of the C-6-C-7 bond, preceded by a hydrogen rearrangement to the charged portion.
The same ion has also been observed in the mass spectra of tirandamycins A and B3'. Further fragmentation of this odd-electron ion results in the formation of ion m/e 126 representing the tetramic acid moiety as well as in that of ion m/e 95 representing its hydrocarbon part. Ion m/e 126 has also been reported in the case of tirandamycin A". Direct cleavage of the C-6-C-7 bond gives rise to ion m/e 283 in the case of 1. The analogous fragmentation process has been reported in the case of tirandamycins A and B3,4) and of methyl streptolate5) but not observed in the spectra of streptolydigin5 The symbol m*(m) at the arrows indicates that the respective metastable transitions have been measured by using accelerating voltage scans. The intensity of the observed metastable peaks are denoted by abbreviations vw (very weak), s (strong) and vs (very strong). Table   1 . Characteristic mass spectral data of compounds 1 and 2. The absolute stereochemical assignment of tirandamycin A and streptolydigin have been reported).
Based upon the high similarity of NMR data it can be assumed that the stereochemistry of nocamycin is the same as that of tirandamycin A as regards portions C-1 to C-10 and C-13 to C-17.
Note added in proof:
After this paper had been submitted for publication a Dutch patent (No. 7807570) was published which describes a compounds (Bu 2313B) whose physico-chemical data seem to be similar to those of nocamycin.
Although not proven, a structure is proposed in that patent for Bu 2313B which differs from that of nocamycin, suggested here in positions C-12-C-14 and C-18-C-21. The structural part proposed there may also fit to our data presented here. 
